Pharmaceutical company Allergan has signed a licensing agreement with AstraZeneca's global biologics research and development arm MedImmune for the global rights to MEDI2070.

MEDI2070 is currently in development for the potential treatment of crohn's disease and ulcerative colitis.

Crohn's disease and ulcerative colitis are chronic inflammatory conditions of the gastrointestinal tract.

As per the agreed terms, AstraZeneca will receive a $250 million upfront payment from Allergan towards worldwide license to develop and commercialise the anti-IL-23 monoclonal antibody.

"We look forward to bringing our significant clinical development and regulatory expertise to bear and maximising the potential benefit of this possible new treatment option for patients."

Allergan may also make potential payments to AstraZeneca of up to $1.27 billion over a period of up to 15 years.

Allergan chief research and development officer David Nicholson said: "MEDI2070 represents an exciting addition to our Open Science pipeline, adding an important new programme currently being studied in Crohn's disease, with potential across a number of inflammatory and autoimmune disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The MEDI2070 programme also reinforces Allergan's commitment to bringing forward important innovations in the treatment of inflammation and autoimmune disorders where significant unmet need exists across many of our therapeutic areas.

"We look forward to bringing our significant clinical development and regulatory expertise to bear and maximising the potential benefit of this possible new treatment option for patients."

Subject to certain customary closing conditions, the transaction is expected to be completed by the fourth quarter of 2016.

Allergan has recently acquired Vitae Pharmaceuticals and its VTP-43742, a Phase 2 first-in-class, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders.